Search clinical trials for: Biological/Vaccine: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)

Total 14 results

Novavax
Department of Health and Human Services

Completed

A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2

Covid19 | SARS-CoV Infection

United States, Mexico, Puerto Rico
Novavax

Active, not recruiting

Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years (COVID-19)

COVID-19

Spain, United States, South Africa, Mexico, United Kingdom, Philippines, Colombia, Dominican Republic, Guatemala, Honduras
Novavax

Completed

Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine

Covid19 | SARS-CoV Infection

Australia
Novavax

Completed

Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA Vaccines

COVID-19

United States
Novavax

Completed

A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom

COVID-19 | SARS-CoV-2 Infection

United Kingdom
Novavax

Completed

Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults

COVID-19 | SARS-CoV-2 Infection

United States
Novavax

Completed

Phase 3 Boosting Study for the SARS-CoV-2 rS Variant Vaccines (COVID-19)

COVID-19 | SARS CoV 2 Infection

Australia
Novavax
Bill and Melinda Gates Foundation

Completed

A Study Looking at the Effectiveness and Safety of a COVID-19 Vaccine in South African Adults

COVID-19 | SARS-CoV-2 Infection

South Africa
Novavax

Completed

A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. (COVID-19)

COVID-19

United States
Novavax

Active, not recruiting

Phase 3 Adolescent Study for SARS-CoV-2 rS Variant Vaccines (COVID-19)

COVID-19

United States
Novavax
Coalition for Epidemic Preparedness Innovations

Completed

Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant

COVID-19

United States, Australia
Novavax

Completed

A Study to Evaluate Safety and Immunogenicity of a COVID-19 Vaccine in People Living With HIV at Risk for SARS-CoV-2 (COVID-19) (COVID-19)

SARS-CoV-2 Infection

South Africa
Sanofi Pasteur, a Sanofi Company

Active, not recruiting

Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older (VAT00008)

COVID-19

United States, Colombia, Ghana, Honduras, India, Japan, Kenya, Mexico, Nepal, Nigeria, Sri Lanka, Uganda, Ukraine
Novavax

Not yet recruiting

A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine

COVID-19

3

Subscribe